Kornimate/medical-research-clean huggingface dataset:
automated screening for clinically ascertained loss of cerebral functions

Conditions: Irreversible Loss of Brain Function (ILBF)

Summary: rationale: the low organ donation rate in germany is associated with the inadequate identification of patients at risk of developing irreversible loss of brain function (ilbf; i.e. brain death). an automated digital screening tool, detect (automated screening for clinically ascertained loss of cerebral functions in patients with severe brain damage), has been developed to prospectively identify intensive care patients who are at risk of developing ilbf. objective: the objective of the study is to evaluate the effectiveness of an automated digital screening tool in the identification of patients with severe brain damage who are at risk of impending ilbf compared to standard practice without digital support. study design: stepped-wedge, multicenter, cluster-randomized, controlled trial study population: the study includes patients aged 18 years or older with primary and/or secondary acute brain damage, requiring mechanical ventilation, and who are deceased upon hospital discharge. intervention: detect periodically processes real-time data from the corresponding electronic medical record system to screen for a combination of coma, indicated by a richmond agitation sedation scale (rass) score of - 4 or - 5 or glasgow coma scale (gcs) score of 6-3, along with manually assessed absence of bilateral pupillary light reflexes. both findings are considered early indicators of impending ilbf. in case of positive screening results, an automated notification will be sent via the hospital's email server to the corresponding transplant coordinators and intensivists. the email sent aims to prompt clinical assessment of the reported patient and, if necessary, initiate a guideline-based ilbf examination. primary study endpoint: the primary endpoint is the identification of patients who eventually develop ilbf during hospitalization. secondary study endpoints: secondary outcomes encompass the missed identification of potential ilbf cases (as retrospectively classified) and the rate of deceased organ donations. upon completion of the study, a survey will be conducted to investigate the stakeholders' experiences with detect.


Eligibility criteria:
inclusion criteria: * primary and/or secondary acute brain damage * at least 18 years or older * necessity of mechanical ventilation * deceased upon hospital discharge exclusion criteria: • none

Keywords: screening detection irreversible loss of brain function death by neurologic criteria brain death organ donation
hypoxic pulmonary vasoconstriction pilot study

Conditions: Emphysema

Summary: the purpose of this study is to determine if the events leading to smoking-associated centrilobular and paraseptal emphysema are caused by a failure of the lungs' inherent mechanisms to block hypoxic pulmonary vasoconstriction (hpv) in areas of smoking-induced inflammation.

overall goals of this study are to 1) determine the effects on sildenafil on the heterogeneity perfused blood volume in smokers susceptible to emphysema using dual energy ct 2) utilize pulmonary blood volume heterogeneity as an image-based biomarker to differentiate normal and susceptible smokers.

Eligibility criteria:
inclusion criteria: * must be between the ages of 30 and 60. * must be currently smoking at least 1/2 pack/day (confirmed with cotinine level). * must have pulmonary function test (pft) results that meet the following: * forced expiratory volume at one second (fev1)/forced vital capacity (fvc) \> 70% * forced expiratory flow at 25-75% (fef25-75) \> 79% of predicted * fvc greater than 80% of predicted * must be able to give informed consent for self. exclusion criteria: * pregnant or breastfeeding females. * body mass index (bmi) greater than 32. * weight of greater than 220 pounds (100 kg). * allergies to shell fish, seafood, eggs or iodine. * heart disease, kidney disease or diabetes. * diagnosis of asthma. * usage of any medications that are known to affect the heart or lungs (contraceptives, anti-depressants, analgesics except aspirin, antihypertensives, and medications for osteoporosis and gastrointestinal diseases will be allowed). * any metal in or on the body between the nose and the abdomen. * any major organ system disease (by judgment of study medical team). for the subjects that will receive sildenafil as part of the study, additional exclusion criteria are as follows: * nitroglycerin usage. * prior history of hypersensitivity to sildenafil.
the halland osteoarthritis cohort

Conditions: Osteoarthritis, Knee; Osteoarthritis Hand; Osteoarthritis Generalized

Summary: osteoarthritis is the most common musculoskeletal disease and is characterized by cartilage destruction, osteophyte formation, subchondral bone sclerosis and cysts. modern treatment strategies, as well as preventive measures, include early detection and knowledge of the early course of the disease. this includes how stress patterns, physical activity, impaired function and metabolic changes and other comorbidities affect development and possible associations with osteoarthritis. the overall objective was to study the early development of osteoarthritis of the knee and its association with hand- and general osteoarthritis, metabolic diseases, biomarkers, long-term pain, physical function and stress patterns

the overall objective was to study the early development of osteoarthritis of the knee and its association with hand- and general osteoarthritis, metabolic diseases, biomarkers, long-term pain, physical function and stress patterns. the project includes 4 different research areas that are studied with the help of several smaller sub-studies: research area 1: metabolic osteoarthritis - to study the connections between metabolic factors and osteoarthritis development in the knee and hand. a. relationship between knee osteoarthritis and metabolic factors b. relationship between osteoarthritis of the hand and metabolic factors research area 2: biomarkers in knee and hand osteoarthritis - to study cartilage and bone markers that reflect different processes in osteoarthritis development, e.g. inflammation, matrix degradation both in the short and long term research area 3: pain and osteoarthritis - to study pain development and pain pressure thresholds in relation to lifestyle, depression and health-related quality of life in individuals with symptomatic knee osteoarthritis research area 4: physical function and osteoarthritis - to study physical function, physical activity and measured stress patterns, as well as changes in stress patterns and the relationship between these and the development of osteoarthritis over time. study design this is a longitudinal cohort study including 306 individuals with knee pain in the southwest of sweden, the halland osteoarthritis (halloa) cohort. the enrolments took place from 2017-2019. the participants were recruited: 1) by primary health care clinics when searching care for knee pain, or 2) by advertisements in local newspapers. the inclusion criterions were current knee pain, aged 30-65 years, with no former known radiographic knee osteoarthritis (rkoa). the exclusion criterions were no cruciate ligament rupture or rheumatologic disorder. a general practitioner examined all participants to confirm the exclusion criteria. the cohort will be followed for five years with yearly follow-ups.

Eligibility criteria:
inclusion criteria: knee pain exclusion criteria: cruciate ligament injury and rheumatic disease (ra, psoa, as, sponylarthritis etc)
safety and efficacy of sofosbuvir and ribavirin in adults with recurrent chronic hepatitis c virus (hcv) post liver transplant

Conditions: Recurrent Chronic Hepatitis C Virus; Post Liver Transplant

Summary: this is an open-label, single-arm study of sofosbuvir (gs-7977) and ribavirin (rbv) in adults who have had a liver transplant which has become re-infected with hepatitis c. the treatment period is 24 weeks with up to 48 weeks of follow up. the total time in this study will last up to 72 weeks not including the screening visit.


Eligibility criteria:
inclusion criteria: * subjects with evidence of chronic hcv (all genotypes) documented pretransplantation * hcv rna ≥ 10,000 iu/ml at screening * absence of organ rejection as documented by post transplant liver biopsy taken no more than 12 months prior to baseline/day 1 visit * liver transplant ≥ 6 months and ≤ 12 years prior to screening * naive to all nucleotide/nucleoside treatments for chronic hcv infection exclusion criteria: * multiorgan transplant that includes heart or lung recipient * subjects with de novo or recurrent hepatocellular carcinoma(hcc) post transplant * current use of corticosteroids at any dose \> 5mg of prednisone/day (or equivalent dose of corticosteroid) * infection with hepatitis b virus (hbv) or hiv at screening * current, uncontrolled ascites, variceal hemorrhage, hepatic encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome, or other signs of decompensated cirrhosis
fluocinolone acetonide intravitreal inserts for vein occlusion in retina

Conditions: Macular Edema; Retinal Vein Occlusion

Summary: this study will assess the safety and efficacy of fa intravitreal inserts in subjects with macular edema secondary to rvo.


Eligibility criteria:
inclusion criteria: * diagnosis of macular edema due to branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo) * central subfield thickness \> 300 μm * bcva of ≥ 24 and ≤ 68 letters * males and non-pregnant females 18 years and over exclusion criteria: * macular edema secondary to any condition other than rvo * presence of foveal atrophy, dense pigmentary changes or dense subfoveal exudates in the study eye * cystic intraretinal hemorrhage involving the fovea in the study eye that is responsible for vision loss * glaucoma or ocular hypertension (iop \> 21 mmhg or concurrent therapy at screening with iop-lowering agents) * any prior treatment with intravitreal, subtenon, or periocular steroid or anti-vegf therapy since the diagnosis of rvo in the study eye * any change in systemic steroid therapy within 3 months of screening * history of vitrectomy in the study eye

Keywords: macular edema secondary to rvo
efficacy of darifenacin and physiotherapy for the treatment of overactive bladder in women

Conditions: Overactive Bladder

Summary: overactive bladder is a common problem among adult women. darifenacin is an antimuscarinic drug that is frequently used as part of the management of the condition. however, current evidence backing its use is limited. this study aims to address darifenacin's effectiveness in adjunct to physiotherapy in treating symptoms due to overactive bladder.


Eligibility criteria:
inclusion criteria: * patients with overactive bladder as diagnosed and confirmed by a urologist. * able to answer the icic, king's health questionnaire and overactive bladder questionnaire. * able and willing to receive urodynamic studies. exclusion criteria: * history of pelvic radiotherapy. * recent pelvic surgery (\<1 year). * history of anti-incontinence surgery. * pregnancy.

Keywords: urinary bladder, overactive darifenacin physiotherapy quality of life
cannabidiol use to reduce cravings in individuals with opioid use disorder on buprenorphine

Conditions: Opioid-use Disorder

Summary: the purpose of this week-long study is to determine the impact of cannabidiol on cue-induced cravings among individuals with opioid use disorder who are stable on sublingual buprenorphine treatment.

studies have indicated that medication treatment for opioid use disorder (oud) with buprenorphine, methadone, or extended-release naltrexone reduces the risk for overdose by 70%. however, treatment dropout rates remain unacceptably high, with approximately 50% of patients discontinuing treatment 6 months after initiation. there is a substantial body of research indicating that high rates of treatment discontinuation are due to the emergence of intense cravings to use illicit opioids in response to cues - which are reminders of the drug such as drug paraphernalia. much of the research so far in improving treatment retention on medications for oud have focused on helping patients learn how to avoid triggers and to manage their cravings if they do emerge, and psychosocial treatments as adjuncts to medications has similarly not been as helpful as hoped. as such, there is a critical need to identify novel strategies that will improve retention in medical treatment for oud, and cannabidiol (cbd) has emerged as a possible adjunct to oud treatment, as it appears to target brain regions that mediate cue-induced cravings. two studies so far have shown that cbd reduces cue-induced cravings for abstinent individuals with oud not taking any medications, but the impact of cbd on cue-induced cravings among individuals stabilized on buprenorphine is not known. given that long-term medication treatment remains the gold-standard approach, a critical question that remains unanswered is whether cbd can be used as an adjunct to buprenorphine treatment to reduce cue-induced cravings. as such, the purpose of this week-long open-label feasibility pilot is to determine the impact of cannabidiol on cue-induced cravings among individuals with opioid use disorder who are stable on sublingual buprenorphine treatment. patients with oud currently receiving treatment with sublingual buprenorphine will be eligible to enroll. the cue-induced cravings assessment will be conducted before and after the cbd administration.

Eligibility criteria:
inclusion criteria: * diagnosis of diagnostic and statistical manual of mental disorders (dsm-5) opioid use disorder, severe * currently in treatment with methadone or buprenorphine exclusion criteria: * requiring level of care higher than outpatient treatment for alcohol, sedative/hypnotics, or stimulants * any current mood episode requiring level of care higher than outpatient treatment * history of psychotic disorder or bipolar disorder * currently pregnant * hepatic liver enzymes greater than 3x upper normal limit * hypersensitivity to cannabinoids or sesame oil (cannabidiol solution comes in sesame oil emulsion) * currently taking any medications with known significant pharmacokinetic interactions with cbd
brighter bites & ut physicians produce rx program

Conditions: Obesity, Childhood

Summary: the purpose of this study is to clinically evaluate the effectiveness of an at-home produce delivery prescription or grocery store vouchers prescription at improving weight status and obesity-related health outcomes of participants across the two clinics as compared to a control group and to examine the impacts of the program on child dietary behavioral outcomes (child fruit and vegetable intake, junk food consumption, and eating at any type of restaurant), and parent feeding practices (preparing foods from scratch, use of nutrition facts labels to make purchasing decisions, and eating meals with their referent child)


Eligibility criteria:
inclusion criteria: * reside within a 10-mile radius of a brighter bites school * medicaid recipients or low-income uninsured * parents must be able to read and write in english or spanish to complete surveys exclusion criteria: * currently participating in brighter bites * with a family member/sibling currently participating in brighter bites * child is currently attending a school that offers brighter bites
analysis of the pathophysiological and functional state of the knee joint

Conditions: Osteoarthritis, Knee; Cartilage Degeneration

Summary: osteoarthritis is the most common degenerative condition affecting the knee joint globally, with an incidence of about 7% of the population. in italy, it affects approximately 3.9 million people, with a direct treatment cost of around €2.5 billion. at the joint level, osteoarthritis manifests with pain and reduced functionality, worsening as the disease progresses and severely limiting knee movement. compounding this, osteoarthritis can impact both elderly and younger individuals due to traumatic factors. despite its significant impact, effective treatments for osteoarthritis that address its underlying causes are still lacking, focusing mainly on symptom management. therefore, improving diagnostic and prognostic approaches is crucial to better understand its onset and progression. mri is a primary diagnostic tool for assessing the knee joint's pathophysiological state. it uses tissue-specific sequences to investigate joint homeostasis in detail, although it primarily provides insights into morphology, structure, and tissue composition rather than functional changes within the joint. this limitation is noteworthy because joint homeostasis involves complex interactions among biomechanical, structural, and biological processes, which are directly influenced by osteoarthritis. gait analysis provides valuable diagnostic information on joint function. by integrating sensor measurements and electronic systems with patient-specific musculoskeletal models derived from mri morphometric data, it is possible to assess the forces and moments within the joint during specific movements. given that osteoarthritis affects the entire joint, employing multidisciplinary approaches can enhance diagnostic precision and provide insights into the progressive impact of degenerative conditions like osteoarthritis on joint health.


Eligibility criteria:
inclusion criteria: * knee pain and/or loss of functionality * kellgren-lawrence grade less than or equal to 2 * arthroscopic evidence of cartilage tissue lesions * evidence of cartilage and/or meniscal tissue degeneration and/or subchondral bone marrow lesions exclusion criteria: * history/evidence of previous partial or total knee prosthesis interventions * inability to provide informed consent * conditions or physical disorders incompatible with the use of mri and electrical stimulation (implanted active and passive biomedical devices, epilepsy, severe venous insufficiency in the lower limbs)
early removal of the urethral catheter following trans-urethral resection of prostate

Conditions: Urinary Retention

Summary: transurethral resection of prostate is the gold standard operation for bladder outflow obstruction due to benign prostatic enlargement. however, catheter removal day is variable. the objective of this study is to compare early and delayed catheter removal groups in terms of, urinary retention after catheter removal, length of hospital stay, weight of resected prostate, duration of resection, peri-operative blood transfusion, and postoperative complications.

this randomized controlled trial will carried out in urology clinic at jordan university hospital. patients with benign prostate hyperplasia will be selected by simple random sampling technique after taking informed consent and will divided into two groups: group a- early catheter removal group( catheter removed after 24 hours) and group b-delayed catheter removal group ( catheter removed after 48 hours). in this study we will exclude patients with large post-void urine volume, simultaneous internal urethrotomy and transurethral resection of prostate, co-morbidity( diabetes mellitus, cva) spinal cord injury, urethral stricture, prostate cancer proved by biopsy and intra-operative complications. patients will discharged after removal of catheter if they voided successfully.

Eligibility criteria:
inclusion criteria: - all men with benign prostate hyperplasia who planned to undergo turp will be included in this study. exclusion criteria: * large post void residual urine. * simultaneous internal urethrotomy and turp. * uncontrolled diabetes mellitus (dm). * cerebrovascular accident accident (cva). * spinal cord injury.

Keywords: benign prostate hyperplasia urinary retention re-catheterization
the effect of dynamic tape ® on plantar fascitis

Conditions: Fasciitis, Plantar; Foot Tapping

Summary: the dynamic tape ® (dt) is a new tape (2009). dynamic tape ® is a visco-elastic nylon tape material , greater than 200% elastic has manufactured in asia. the material and adhesive arefast drying and breathable meaning that the tape, if it is correctly applied may stay on for up to 5 days, bearingin mind that if any discomfort, itching, burning, stinging orirritation is felt immediate removal is strongly advised. usually tapes are applied in plantar fasciitis to improve the symptoms. the fasciitis plantar is an pain that sometimes incapacitates the physical activity of the patients.

objective: to evaluate the evolution of this symptomatology prior to and thereafter the application of dynamic tape® bandage in a sample of 15 amateur athletes affected by plantar fasciitis. the assessment will be performed using an analogue visual scale (eva). material and methods: the aim of the study is to evaluate a group of 15 amateur athletic subjects , all individuals suffering plantar fasciitis without any previous or current treatment. the age, from 18 to 65 years old. samplings will be performed intentionally without a control group. the control group will use a low-dye tape and will be evaluated before and after a week

Eligibility criteria:
inclusion criteria: * clinical diagnosis of fasciitis * plantar fasciitis pain exclusion criteria: current treatment of fasciitis pain

Keywords: foot fasciitis tapping
multi-center, prospective, randomized, comparison of awbat™-d vs. xeroform™ or glucan ii™ for treatment of donor sites in burn surgery

Conditions: Treatment of Donor Site Burns

Summary: the purpose of this study is to compare the rate of healing and the non-adherence of three types of dressings. the study will also compare rate of infection, scarring and perception of pain associated with treatment.

the purpose of this study is to evaluate awbat™-d compared to xeroform™ or glucan ii™ for the treatment of donor sites in burn surgery. primary study goals: * to compare the rate of healing of donor sites. * to compare patient reported perception of pain * to compare the potential clinical complication rates of: * non-adherence, * seroma * hematoma * infection secondary study goal: • to compare clinical outcome of donor sites: scarring based on the vancouver scar scale.

Eligibility criteria:
inclusion criteria: * burn wounds measuring 1% - 30% tbsa requiring skin grafting * anterior bilateral donor sites of approximately the same size taken from the thighs or abdomen exclusion criteria: * ventilator dependence * pregnancy /lactation * mechanism of injury was electrical, chemical or frostbite * co-morbidity which may compromise healing * known allergy to porcine or porcine products

Keywords: burn, donor site, skin graft, dressing, awbat™-d, xeroform™, glucan ii™
cognitive characteristics of ptsd patients with ocd

Conditions: Post-Traumatic Stress Disorders; Obsessive-Compulsive Disorder

Summary: cognitive profile of patients who suffer both from ptsd and ocd, as compared to those who suffer from ptsd or ocd without other comorbidity.

demographic data and cognitive data will be compared on ptsd, ptsd-ocd and ocd patients using a battery of computerized cognitive tests

Eligibility criteria:
inclusion criteria: * patients suffer from current ptsd with no other co-morbidity * patients suffer from current ocd with no other co-morbidity * patients suffer from current ptsd and ocd exclusion criteria: * patients suffer from ptsd and oc symptoms